Herpes Zoster (Shingles) – Pipeline Review, H1 2013


February 28, 2013
48 Pages - SKU: GMD4986680
License type:
Table of Contents Search inside this report Related Reports
Introduction
Global Markets Direct Report Coverage
Herpes Zoster (Shingles) Overview
Therapeutics Development
An Overview of Pipeline Products for Herpes Zoster (Shingles)
Herpes Zoster (Shingles) Therapeutics under Development by Companies
Herpes Zoster (Shingles) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Herpes Zoster (Shingles) Therapeutics – Products under Development by Companies
Herpes Zoster (Shingles) Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Herpes Zoster (Shingles) Therapeutics Development
GlaxoSmithKline plc
Merck & Co., Inc.
aRigen Pharmaceuticals, Inc.
Epiphany Biosciences, Inc.
Synergy Pharmaceuticals, Inc.
Herpes Zoster (Shingles) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
FV-100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
valomaciclovir stearate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zoster - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Varicella-zoster vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
V-212 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-1437173A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Herpes Zoster (Shingles) Therapeutics – Drug Profile Updates
Herpes Zoster (Shingles) Therapeutics – Discontinued Products
Herpes Zoster (Shingles) Therapeutics - Dormant Products
Herpes Zoster (Shingles) – Product Development Milestones
Featured News & Press Releases
Jul 18, 2012: Agenus Annnounces Intiation Of Phase III Clinical Trial Of GSK's Herpes Zoster Vaccine Candidate In Immunocompromised Patients
Feb 01, 2012: Asahi Kasei Pharma Files Application For Approval Of Famvir Anti-herpes Agent For Additional Indication
Dec 13, 2010: Inhibitex Reports Promising Top-Line Results From Phase II Shingles Trial With FV-100
Oct 15, 2010: Inhibitex Completes Enrollment In Phase II Clinical Trial Of FV-100 In Shingles Patients
Aug 23, 2010: GSK Initiates Phase III Clinical Trials To Develop Herpes Zoster Vaccine For Prevention Of Shingles
Jul 22, 2010: Inhibitex Reports Independent Data Safety Monitoring Board Recommends Continuation Of Phase II Clinical Trial Of FV-100
Nov 18, 2009: Epiphany Announces Positive Results Of Its Drug Candidate Valomaciclovir From Its Phase 2b Trial In Shingles
Sep 09, 2008: Epiphany Biosciences Announces To Continue Phase 2 shingles Study After Interim Analysis
Nov 07, 2007: Epiphany Biosciences Reports Initiation And Enrollment In Valomaciclovir Study For Shingles
Dec 05, 2006: aRigen Group Announces Successful Phase II Study Of ARYS-01 (Sorivudine) Cream
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Herpes Zoster (Shingles), H1 2013
Products under Development for Herpes Zoster (Shingles) – Comparative Analysis, H1 2013
Number of Products under Development by Companies, H1 2013
Number of Products under Investigation by Universities/Institutes, H1 2013
Comparative Analysis by Late Stage Development, H1 2013
Comparative Analysis by Mid Clinical Stage Development, H1 2013
Products under Development by Companies, H1 2013
Products under Investigation by Universities/Institutes, H1 2013
GlaxoSmithKline plc, H1 2013
Merck & Co., Inc., H1 2013
aRigen Pharmaceuticals, Inc., H1 2013
Epiphany Biosciences, Inc., H1 2013
Synergy Pharmaceuticals, Inc., H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Stage and Molecule Type, H1 2013
Herpes Zoster (Shingles) Therapeutics – Drug Profile Updates
Herpes Zoster (Shingles) Therapeutics – Discontinued Products
Herpes Zoster (Shingles) Therapeutics – Dormant Products
List of Figures
Number of Products under Development for Herpes Zoster (Shingles), H1 2013
Products under Development for Herpes Zoster (Shingles) – Comparative Analysis, H1 2013
Products under Development by Companies, H1 2013
Products under Investigation by Universities/Institutes, H1 2013
Late Stage Products, H1 2013
Mid Clinical Stage Products, H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Route of Administration, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Molecule Type, H1 2013
Assessment by Stage and Molecule Type, H1 2013
 
Research assistance
We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 
Related Markets

Drug Discovery Reports
 
 

Share this report


Other tasks

 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!